BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Reputational Risks
Australia's First Confirmed Peptide Fatality: What the CJC-1295 and Ipamorelin Coroner's Findings Mean for Research Procurement
A Victorian coroner has found that the March 2025 death of Australian actor Richard Norton was triggered by injections of unapproved peptides CJC-1295 and Ipamorelin, recommending the TGA consider reclassifying both substances to restrict their use to clinical trials. The case — believed to be Australia's first confirmed peptide fatality — has heightened regulatory scrutiny internationally and carries direct implications for research institutions handling growth-hormone-releasing peptides.
04 Nov 2026
Reputational Risks
Filthy Warehouse, 12,000 Counterfeit Pens, and a Clinic Inquiry: What the MHRA's October Enforcement Blitz Means for UK Research Procurement
A joint MHRA and West Midlands Police raid on 14 October seized more than 12,000 counterfeit retatrutide and tirzepatide pens — worth an estimated £2 million — from a Birmingham industrial unit. Paired with an ongoing MHRA inquiry into private clinics making unsubstantiated peptide claims, the month illustrates how UK enforcement against illicit GLP-1 and research-peptide supply chains is escalating well beyond symbolic warnings.
23 Oct 2026
Reputational Risks
Two Deaths, Eleven Lawsuits, and a Congressional Letter: The Mounting Enforcement Response to Illicit Retatrutide
The illicit market for retatrutide — an experimental triple-receptor agonist still in clinical trials — has reached a new threshold of harm. Two adverse-event deaths have been reported to the FDA, Eli Lilly has now filed eleven lawsuits against black-market sellers, and a bipartisan group of lawmakers wrote to the FDA on 20 October urging closure of the importation loophole. Research procurement teams sourcing investigational peptides need to understand the legal and safety signals this…
21 Oct 2026
Reputational Risks
Sterility Failure at a Forewarned Compounder: What the Apothecary Pharma Tirzepatide Recall Reveals About Persistent Quality Gaps
The FDA has classified a nationwide recall of 22 compounded tirzepatide vials from Apothecary Pharma LLC as a Class II action, citing a lack of sterility assurance — nearly a year after issuing the same pharmacy a warning letter for identical deficiencies. The case illustrates how prior regulatory notice has not prevented sterility failures from recurring in the compounded GLP-1 sector.
20 Oct 2026
Reputational Risks
Black Mould, Falsified Records, and Import Alert 66-40: What FDA Inspection Reports Reveal About Chinese GLP-1 API Suppliers
FDA inspection reports obtained under FOIA reveal black mould on equipment, insect contamination, destruction of samples during inspection, and falsified documentation at two Chinese manufacturers of semaglutide and tirzepatide active pharmaceutical ingredients. Both firms — Chengdu Shengnuo Biopharm and Nanjing Chengong Pharmaceutical — have been placed on Import Alert 66-40, with direct implications for compounding pharmacy supply chains and research-procurement quality assurance.
16 Oct 2026
Reputational Risks
Supplement-Grade API in Injectable Vials: The Glutathione Contamination Cluster That Illuminates a Systemic Compounding Risk
At least four US compounding pharmacies have recalled injectable glutathione products since August 2026 after elevated endotoxin levels were traced to a supplement-grade active pharmaceutical ingredient. Dozens of people have been sickened across multiple states. For research-procurement professionals, the cluster illustrates the specific hazard of API provenance gaps that can affect any compounded peptide injectable — not only the compounds currently under regulatory scrutiny.
15 Oct 2026
Reputational Risks
The FDA's Enforcement Paradox: Warning Letters, Import Bans, and China Supply Chain Scrutiny as Deregulation Signals Grow
Even as the Trump administration signals a more permissive posture towards certain restricted peptides, FDA enforcement has simultaneously accelerated across three fronts: warning letters to online sellers, a criminal prosecution yielding a 70-month sentence, and import bans on Chinese peptide API manufacturers. Research procurement teams need to understand both currents.
10 Oct 2026
Reputational Risks
FDA's September 2026 Peptide Vendor Sweep: Five Warning Letters, the "Research-Use Only" Labelling Test, and What It Means for Legitimate Suppliers
On 1 September 2026, the FDA published five simultaneous warning letters to online peptide sellers, citing the illegal marketing of injectable semaglutide, tirzepatide, retatrutide, tesamorelin and other unapproved compounds. The sweep expands an established enforcement pattern and clarifies how regulators assess "research-use only" claims — with direct implications for compliant research-grade suppliers in the UK and US.
22 Sep 2026
Reputational Risks
Three Texas Recalls in Six Weeks: How Dietary-Grade Glutathione API Triggered a Compounding Safety Crisis — and What State Boards Are Now Saying About Research-Grade Peptides
Three Texas compounding pharmacies recalled injectable glutathione products between August and September 2026 after elevated bacterial endotoxin levels were traced to a shared dietary-supplement-grade API source. With at least 39 adverse events on record, the episode illustrates a recurring quality failure the FDA first warned about in 2019. Separately, Mississippi and South Carolina issued near-identical joint statements in August 2026 barring licensed providers from compounding…
17 Sep 2026
Reputational Risks
FDA's September 2026 Peptide Vendor Sweep: Five Warning Letters, One Clear Doctrine on "Research Use Only" Claims
On 1 September 2026, the FDA posted five coordinated warning letters to online peptide vendors — Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC — each cited for marketing unapproved drugs under the guise of research-use-only labelling. The sweep reinforces a doctrine the agency has applied with increasing consistency: website context, bundled reconstitution guides, and dosing calculators can establish human-use intent…
11 Sep 2026
Reputational Risks
Paradigm Peptides Owner Sentenced to 70 Months: What the First Major Criminal Conviction in the Research-Use-Only Market Means for Research Procurement
A US federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison on 30 July 2026, after he admitted importing unapproved drugs from China and India and misrepresenting them as domestically manufactured, FDA-registered products. The case is widely regarded as the first significant criminal prosecution in the largely unregulated "research-use only" peptide marketplace, and it carries direct implications for research procurement officers assessing supplier risk.
31 Aug 2026
Reputational Risks
Compounded GLP-1s and the Additive Problem: What a Tirzepatide-B12 Impurity Study Means for Research Quality Standards
A peer-reviewed study has identified a novel, widespread chemical impurity in mass-compounded tirzepatide products blended with vitamin B12 — a finding that reinforces wider concerns about additive contamination in peptide supply chains and carries direct lessons for research-grade quality assurance.
04 Aug 2026